Role of Immunity in Pediatric Lymphomas: From Lymphomagenesis to Treatment

Dear Colleagues,

In recent years, we have been witnessing head-spinning advancements in the field of cancer treatment using immune response modification ranging from monoclonal antibodies to immune checkpoint inhibitors to various cell therapies. These achievements have not only renewed interest in understanding the role of immune surveillance breakdown in tumorigenesis, but are also leading to more sophisticated therapeutic modalities that are in the process of development.

With the current approaches utilizing chemotherapy and radiotherapy in some forms and certain cases of lymphomas, a significant group of children are achieving long-term survival. Improvement efforts focus on both the treatment of recurrent and refractory Hodgkin and non-Hodgkin lymphoma and the development of less-toxic therapeutic modalities in both the short- and long-term. As is often the case, experience in adult patients is helping in the design of pediatric clinical trials. An update on the current state of childhood lymphomas with special emphasis on its relation to the immune system could be a valuable resource for clinicians and researchers interested in the field. Therefore, we want to prepare this Special Edition entitled “Role of Immunity in Pediatric Lymphomas: From Lymphomagenesis to Treatment”, to be published in Cancers.

I plan for the following topics to be included in the Issue, though other related areas are welcome as well: 1. Role of the immune system in lymphomagenesis; 2. Hereditary conditions associated with lymphoma development; 3. Role of viruses in childhood lymphomas, with an emphasis on Epstein–Barr virus; 4. Monoclonal antibody therapies in childhood lymphoma therapy; 5. Immune checkpoint inhibitors in lymphoma therapy: adult experience; 6. Pediatric experience on immune checkpoint inhibitors in lymphoma therapy; 7. Hematopoietic stem cell transplantation in childhood lymphomas; 8. Gene therapy: experience in chimeric antigen receptor-T cell therapy in lymphoma: adult experience; 9. T cell therapy in childhood lymphomas.

I hope you will consider participating in this Special Issue of Cancers. Please let us know if you have any questions.

Dr. Süreyya Savaşan
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• childhood
• Hodgkin lymphoma
• non-Hodgkin lymphoma
• lymphomagenesis
• immune deficiency/dysregulation
• EBV
• monoclonal antibodies
• hematopoietic stem cell transplantation
• immunotherapy
• cell therapy